Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The PTEN conundrum: how to target PTEN-deficient prostate cancer

Turnham, Daniel J. ORCID:, Bullock, Nicholas, Dass, Manisha S., Staffurth, John N. ORCID: and Pearson, Helen B. ORCID: 2020. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9 (11) , 2342. 10.3390/cells9112342

[thumbnail of BULLOCK, Nicholas - The PTEN Conundrum How to Target PTEN-Deficient Prostate Cancer.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview


Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to advanced prostate cancer progression and poor clinical outcome. Accordingly, several therapeutic approaches are currently being explored to combat PTEN-deficient tumors. These include classical inhibition of the PI3K–AKT–mTOR signaling network, as well as new approaches that restore PTEN function, or target PTEN regulation of chromosome stability, DNA damage repair and the tumor microenvironment. While targeting PTEN-deficient prostate cancer remains a clinical challenge, new advances in the field of precision medicine indicate that PTEN loss provides a valuable biomarker to stratify prostate cancer patients for treatments, which may improve overall outcome. Here, we discuss the clinical implications of PTEN loss in the management of prostate cancer and review recent therapeutic advances in targeting PTEN-deficient prostate cancer. Deepening our understanding of how PTEN loss contributes to prostate cancer growth and therapeutic resistance will inform the design of future clinical studies and precision-medicine strategies that will ultimately improve patient care. View Full-Text Keywords: PTEN; PI3K; targeted therapy; prostate cancer

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Biosciences
European Cancer Stem Cell Research Institute (ECSCRI)
Additional Information: Attribution 4.0 International (CC BY 4.0)
Publisher: MDPI
ISSN: 2073-4409
Funders: Cancer Research UK
Date of First Compliant Deposit: 9 November 2020
Date of Acceptance: 20 October 2020
Last Modified: 30 Jun 2023 04:06

Citation Data

Cited 16 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics